Fig. 3From: A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanomaChanges in immune checkpoint expression of peripheral blood regulatory T cells with therapy. Compared to responders, non-responders show a relative increase in the expression of multiple immune checkpoint molecules on regulatory T cells on treatment including [41BB (p = 0.04), CTLA4 (p = 0.01), and LAG3 (p = 0.02)]Back to article page